Compare GSK plc (GSK) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Schwab US Dividend Equity ETF — how do they compare? GSK plc trades at $46.64 (market cap $91.88B), while Schwab US Dividend Equity ETF trades at $33.03 (market cap $110.56B). The key difference: Schwab US Dividend Equity ETF is the larger of the two by market cap, and GSK plc pays a 3.9% dividend while Schwab US Dividend Equity ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| GSK | SCHD | |
|---|---|---|
Market Cap | $91.88B | $110.56B |
Volume | 7,730,529 | 23,539,168 |
Sector | Health | Broad Market / Factor |
52-Week High | $61.18 | $35.21 |
52-Week Low | $43.24 | $26.44 |
Typical Hold Time | 93 Days | 62 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
SCHD trades at $33.09, up 1.35% with a bullish technical signal despite mixed moving averages. Recent news highlights its outperformance versus the S&P 500 in 2026 and dividend growth, though the ETF faces pressure from rising interest rates. Support sits at $32-$33, with resistance at $33-$34. The RSI readings are neutral, while ADX signals conflicting trend strength.
Outlook: SCHD offers income growth and lower fees, appealing for dividend investors, but interest rate sensitivity and defensive tilts pose risks. The ETF's rule-based approach may miss high-growth stocks, as seen with Broadcom. Near-term performance hinges on macroeconomic trends and dividend sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
